onr:"swepub:oai:DiVA.org:uu-516106"
Sökning: onr:"swepub:oai:DiVA.org:uu-516106" > Appraisal of the ca...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04327naa a2200457 4500 | |
| 001 | oai:DiVA.org:uu-516106 | |
| 003 | SwePub | |
| 008 | 231116s2023 | |||||||||||000 ||eng| | |
| 009 | oai:prod.swepub.kib.ki.se:236936261 | |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5161062 URI |
| 024 | 7 | a https://doi.org/10.1136/bmjmed-2022-0003352 DOI |
| 024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:2369362612 URI |
| 040 | a (SwePub)uud (SwePub)ki | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Larsson, Susanna C.u Karolinska Institutet,Uppsala universitet,Medicinsk epidemiologi,Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.4 aut0 (Swepub:uu)susla720 |
| 245 | 1 0 | a Appraisal of the causal effect of plasma caffeine on adiposity, type 2 diabetes, and cardiovascular disease :b two sample mendelian randomisation study |
| 264 | c 2023-03-30 | |
| 264 | 1 | b BMJ Publishing Group Ltd,c 2023 |
| 338 | a electronic2 rdacarrier | |
| 520 | a OBJECTIVE: To investigate the potential causal effects of long term plasma caffeine concentrations on adiposity, type 2 diabetes, and major cardiovascular diseases.DESIGN: Two sample mendelian randomisation study.SETTING: Genome-wide association study summary data for associations of two single nucleotide polymorphisms associated with plasma caffeine at the genome-wide significance threshold (rs2472297 near the CYP1A2 gene and rs4410790 near the AHR gene) and their association with the outcomes.PARTICIPANTS: Primarily individuals of European ancestry participating in cohorts contributing to genome-wide association study consortia.MAIN OUTCOME MEASURES: Outcomes studied were body mass index, whole body fat mass, whole body fat-free mass, type 2 diabetes, ischaemic heart disease, atrial fibrillation, heart failure, and stroke.RESULTS: Higher genetically predicted plasma caffeine concentrations were associated with lower body mass index (beta -0.08 standard deviation (SD) (95% confidence interval -0.10 to -0.06), where 1 SD equals about 4.8 kg/m2 in body mass index, for every standard deviation increase in plasma caffeine) and whole body fat mass (beta -0.06 SD (-0.08 to -0.04), 1 SD equals about 9.5 kg; P<0.001) but not fat-free mass (beta -0.01 SD (-0.02 to -0.00), 1 SD equals about 11.5 kg; P=0.17). Higher genetically predicted plasma caffeine concentrations were associated with a lower risk of type 2 diabetes in two consortia (FinnGen and DIAMANTE), with a combined odds ratio of 0.81 ((95% confidence interval 0.74 to 0.89); P<0.001). Approximately half (43%; 95% confidence interval 30% to 61%) of the effect of caffeine on type 2 diabetes was estimated to be mediated through body mass index reduction. No strong associations were reported between genetically predicted plasma caffeine concentrations and a risk of any of the studied cardiovascular diseases.CONCLUSIONS: Higher plasma caffeine concentrations might reduce adiposity and risk of type 2 diabetes. Further clinical study is warranted to investigate the translational potential of these findings towards reducing the burden of metabolic disease. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng |
| 653 | a Cardiology | |
| 653 | a Diabetes mellitus | |
| 653 | a Epidemiology | |
| 653 | a Genetics | |
| 653 | a medical | |
| 653 | a Preventive medicine | |
| 653 | a Public health | |
| 700 | 1 | a Woolf, Benjamin4 aut |
| 700 | 1 | a Gill, Dipender4 aut |
| 710 | 2 | a Uppsala universitetb Medicinsk epidemiologi4 org |
| 773 | 0 | t BMJ medicined : BMJ Publishing Group Ltdg 2:1q 2:1x 2754-0413 |
| 856 | 4 | u https://doi.org/10.1136/bmjmed-2022-000335y Fulltext |
| 856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1812547/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-516106 |
| 856 | 4 8 | u https://doi.org/10.1136/bmjmed-2022-000335 |
| 856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:236936261 |
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Larsson, Susanna ...
- Woolf, Benjamin
- Gill, Dipender
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Endokrinologi oc ...
- Artiklar i publikationen
- BMJ medicine
- Av lärosätet
- Uppsala universitet
- Karolinska Institutet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
